Quintiles adds TMD to oncology portfolio
This article was originally published in Clinica
Executive Summary
Professional healthcare services company Quintiles Transnational has strengthened its oncology offering by purchasing Targeted Molecular Diagnostics (TMD), a laboratory specialising in tissue-based testing. The deal provides Quintiles (Research Triangle Park, North Carolina) with in-house pathology capabilities for tissue-based testing, which the firm describes as being “a critical component of the modern-day oncology drug development process”. According to Quintiles’ senior vice-president Tom Wollman, TMD also gives the company access to important biomarker expression analysis know-how. Westmont, Illinois-based TMD also supports clinical trials for both biotech and pharmaceutical companies around the world, and offers more than 100 biomarker assays. Financial terms of the acquisition were not revealed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals